IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: I. Luttichuys who wrote (181)	12/8/1996 8:59:00 PM
From: Brad C. Dunlap	of 1762

Hi Bennett, I just returned from ASH conference and am very pleased with what info was disclosed. The following are some of the highlights that we will hear about tomorrow. The # of patients with intent to treat 166, # of patients evaluable for the study 151, 9 complete responces or 6%, 67 partial responces or 44%, total CR and PR 50% in evaluable patients. The BCL-2 info is also very impressive and like the efficacy is similar to earlier results.This info was released at the poster presentations that started Saturday morning. Tomorrow, Idec will give the formal presentation on all info including the C2B8/Chemo which was as posted earlier on this thread. As expected the company shied away from any talk on early FDA approval other then what was stated before[ file NDA 1st half of 97 and expect approval 2nd half]. Once again the side effect profile is very positive with efficacy results similar to chop but without the severe toxicities. The oncologists that I spoke with expect the product to eventually be prescribed as a frontline therapy once they become comfortable with the product. Informally, I was told that there are retreat studies being performed and off the record appear to be exciting. Much more work needs to be performed in this area as well as establishing some type of maintenance program. I also attented a presentation on Chronic Lymphocytic Leukemia [CLL] by Dr. Rai who is undoubtedly the foremost authority on this disease. When he came to the slide on future therapies he had listed Idec-C2B8. Idec and the National Cancer Institute have been discussing a future trial. This could happen late 1997 or early 1998. I did not see or hear of any results from other competitive products that were as exciting. Coulter Pharm was present but did not have any additional data. However, there could be some intriqing presentations tomorrow. In summary, it is only a question of time before this product is availble to NHL patients. My wife is calling so I got to run. Should be an interesting week.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next